Sentiment Trading

Regulus Therapeutics Inc. is facing market scrutiny and a stock downgrade, with investors and analysts questioning its financial health and future earnings potential.

Regulus Therapeutics Inc. has agreed to be acquired by Novartis for $1.7 billion, with the deal expected to be completed in the second quarter of 2025, marking a strategic move by Novartis to bolster its position in microRNA therapeutics.

Regulus Therapeutics Inc. is a biotech leader at the forefront of innovation, with a focus on developing treatments for critical health challenges and a strong potential for future growth.